Literature DB >> 29300046

Hepatocellular carcinoma in 2017: Two large steps forward, one small step back.

Marcus-Alexander Wörns1, Peter R Galle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29300046     DOI： 10.1038/nrgastro.2017.174

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  8 in total

Review 1.  The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.

Authors:  Peter R Galle; Francesco Tovoli; Friedrich Foerster; Marcus A Wörns; Alessandro Cucchetti; Luigi Bolondi
Journal:  J Hepatol       Date:  2017-03-18       Impact factor: 25.083

2.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Authors:  Tim Meyer; Richard Fox; Yuk Ting Ma; Paul J Ross; Martin W James; Richard Sturgess; Clive Stubbs; Deborah D Stocken; Lucy Wall; Anthony Watkinson; Nigel Hacking; T R Jeffry Evans; Peter Collins; Richard A Hubner; David Cunningham; John Neil Primrose; Philip J Johnson; Daniel H Palmer
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-06-23

3.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 4.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

5.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

Review 6.  HCC therapies--lessons learned.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 46.802

7.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  8 in total
  10 in total

1.  Anti-Cancer Effect of Moroccan Cobra Naja haje Venom and Its Fractions against Hepatocellular Carcinoma in 3D Cell Culture.

Authors:  Ayoub Lafnoune; Su-Yeon Lee; Jin-Yeong Heo; Imane Gourja; Bouchra Darkaoui; Zaineb Abdelkafi-Koubaa; Fatima Chgoury; Khadija Daoudi; Salma Chakir; Rachida Cadi; Khadija Mounaji; Najet Srairi-Abid; Naziha Marrakchi; David Shum; Haeng-Ran Seo; Naoual Oukkache
Journal:  Toxins (Basel)       Date:  2021-06-04       Impact factor: 4.546

Review 2.  Circular RNAs in hepatocellular carcinoma: Functions and implications.

Authors:  Liyun Fu; Zhenluo Jiang; Tianwen Li; Yaoren Hu; Junming Guo
Journal:  Cancer Med       Date:  2018-06-01       Impact factor: 4.452

3.  Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma.

Authors:  Nicola Personeni; Tiziana Pressiani; Lorenza Rimassa
Journal:  Health Sci Rep       Date:  2020-01-29

4.  TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma.

Authors:  Jicheng Duan; Youwen Qian; Xiaohui Fu; Meiling Chen; Kai Liu; Hu Liu; Jiahe Yang; Chen Liu; Yanxin Chang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

5.  Hsa_circ_0008537 facilitates liver carcinogenesis by upregulating MCL1 and Snail1 expression via miR‑153‑3p.

Authors:  Ge Yang; Xianyong Li; Jingbo Liu; Shengjie Huang; Yaguang Weng; Jing Zhu; Daiqiong Lin; Ou Jiang
Journal:  Oncol Rep       Date:  2021-01-19       Impact factor: 3.906

6.  Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway.

Authors:  Xudong Liu; Jie Gao; Yaohui Sun; Feng Zhang; Wenzhi Guo; Shuijun Zhang
Journal:  Drug Des Devel Ther       Date:  2022-03-29       Impact factor: 4.162

Review 7.  Systemic Treatment Options in Hepatocellular Carcinoma.

Authors:  Lorenza Rimassa; Tiziana Pressiani; Philippe Merle
Journal:  Liver Cancer       Date:  2019-05-29       Impact factor: 11.740

8.  TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network.

Authors:  Dawei Chen; Jixue Zou; Zhenguo Zhao; Xiaodong Tang; Zhicheng Deng; Jingchao Jia; Shuanghai Liu
Journal:  Cell Death Dis       Date:  2018-10-31       Impact factor: 8.469

9.  Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11.

Authors:  Zhicheng Yao; Ruiyun Xu; Lin Yuan; Mingxing Xu; Haiyun Zhuang; Yanjie Li; Yi Zhang; Nan Lin
Journal:  Cell Death Dis       Date:  2019-12-10       Impact factor: 8.469

10.  CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation.

Authors:  Shijun Yu; Jingde Chen; Ming Quan; Li Li; Yandong Li; Yong Gao
Journal:  J Cell Mol Med       Date:  2020-12-04       Impact factor: 5.295
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.